Molecular analysis of pediatric solid tumors
Molecular Analysis Of Solid Tumors
This study is trying to understand the genetic and molecular features of different childhood solid tumors to find better ways to treat these tough cancers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | N/A to 25 Years |
| Sex | All |
| Sponsor | St. Jude Children's Research Hospital Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Memphis, Tennessee) |
| Trial ID | NCT01050296 on ClinicalTrials.gov |
What this trial studies
This observational study aims to characterize the molecular, cellular, and genetic properties of various pediatric solid tumors, including neuroblastoma, osteosarcoma, and retinoblastoma. It will involve collecting tumor specimens for gene expression analysis, genomic profiling, and next-generation sequencing. Additionally, the study will examine T cell receptor specificity and perform epigenetic studies to understand the anti-tumor response. The goal is to identify changes in gene expression and correlate them with genetic alterations to improve treatment strategies for these aggressive cancers.
Who should consider this trial
Good fit: Ideal candidates include children and young adults up to 25 years old with a suspected or confirmed diagnosis of specific pediatric solid tumors.
Not a fit: Patients with tumors that are not part of the specified conditions or those who are not eligible for tissue collection may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more targeted and effective treatments for pediatric solid tumors.
How similar studies have performed: Other studies focusing on molecular characterization of pediatric tumors have shown promise, indicating that this approach could yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Must have a suspected or known diagnosis of neuroblastoma, osteosarcoma, Ewing sarcoma family of tumor or soft tissue sarcoma based on the initial diagnostic workup and evidence of gross disease amenable to excision. Specimens may be collected at some or all of the following time points: initial biopsy, bone marrow aspiration procedures, tumor resection, and at time of possible relapse. * Patients with a diagnosis of retinoblastoma based on initial diagnostic workup and who require enucleation may be enrolled if there is no active therapeutic or biologic protocol for retinoblastoma. * The patient or his/her legal guardian, as appropriate, must provide written informed consent within 30 days of the removal of the first collection of tissue/bone marrow/blood sample for this protocol. * The patient is being seen at St. Jude Children's Research Hospital or at a collaborating institution. * Patients must be less than or equal to 25 years old at the time of enrollment. Exclusion Criteria: * Patient is known to be Hepatitis B, Hepatitis C and/or HIV positive.
Where this trial is running
Memphis, Tennessee
- St. Jude Children's Research Hospital — Memphis, Tennessee, United States (Recruiting)
Study contacts
- Principal investigator: Sara M. Federico, MD — St. Jude Children's Research Hospital
- Study coordinator: Sara M. Federico, MD
- Email: referralinfo@stjude.org
- Phone: 1-866-278-5833
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.